Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Coverage Leads Indian Drug Makers Into Ties With Foreign Firms

This article was originally published in PharmAsia News

Executive Summary

India's three year old ban on generic copies of drugs still under patent coverage has led the pharma industry to turn to inlicensing and strategic marketing deals with foreign companies. A pharma researcher said the deals offer higher margins, between 25 percent and 35 percent, without competition from other generics. Ranbaxy Laboratories has the largest number of ties with other drug makers, allowing it to launch 12 new products in the recent three month period. The ties also lower the amount of investments needed in the business and fewer risks. (Click here for more
UsernamePublicRestriction

Register

SC068468

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel